Citation Impact
Citing Papers
Subacute toxicity evaluation of a new camptothecin anticancer agent CKD-602 administered by intravenous injection to rats
2004
Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)
2004
Etoposide: four decades of development of a topoisomerase II inhibitor
1998 Standout
Conjugation of Camptothecins to Poly‐(l‐Glutamic Acid)
2000
Hyperthermia in combined treatment of cancer
2002 Standout
Clinical trials in primary hepatocellular carcinoma: current status and future directions
1988
Hepatocellular carcinoma
2018 Standout
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Synthesis of Biomolecule‐Modified Mesoporous Silica Nanoparticles for Targeted Hydrophobic Drug Delivery to Cancer Cells
2011 StandoutNobel
Nanoparticles in Medicine: Therapeutic Applications and Developments
2007 Standout
Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma
2003
XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer
2009
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours
2004
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Metabolism and reactions of quinoid anticancer agents
1987
A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38
1995
Clinical Pharmacokinetics of Topotecan
1996
Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin
1991
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
2003 Standout
Novel 7-Alkyl Methylenedioxy-Camptothecin Derivatives Exhibit Increased Cytotoxicity and Induce Persistent Cleavable Complexes Both with Purified Mammalian Topoisomerase I and in Human Colon Carcinoma SW620 Cells
1997 StandoutNobel
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
1999 Standout
Nanoparticles in cancer therapy and diagnosis
2002 Standout
Single-Dose Toxicity Study of Hepatic Intra-arterial Infusion of Doxorubicin Coupled to a Novel Magnetically Targeted Drug Carrier
2001
Cinnamic Acid Derivatives as Anticancer Agents-A Review
2011
Preclinical and clinical studies of anticancer drug-incorporated polymeric micelles
2007
Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors
2003
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
2021 Standout
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
1997
Biomedical applications of biodegradable polymers
2011 Standout
Differential Stabilization of Eukaryotic DNA Topoisomerase I Cleavable Complexes by Camptothecin Derivatives
1995 StandoutNobel
Management of Hepatocellular Carcinoma *
2005 Standout
Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function
1995
Polymer conjugates as anticancer nanomedicines
2006 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Clinical Pharmacokinetics of Doxorubicin
1988
Superparamagnetic iron oxide nanoparticles (SPIONs): Development, surface modification and applications in chemotherapy
2010 Standout
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
2001 Standout
Topoisomerase Inhibitors
1995
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
1996
Advances and Challenges of Liposome Assisted Drug Delivery
2015 Standout
Prognostic Factors in Patients With Hepatocellular Carcinoma Receiving Systemic Chemotherapy
1992
Chronic hepatitis B
2007 Standout
DNA Topoisomerases: Essential Enzymes and Lethal Targets
1994
Recombinant α2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial
1989
Interaction of Hyperthermia and Chemotherapy
1988
Doxorubicin clearance in the obese.
1988
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of an Orally Active Novel Camptothecin Analog, DRF‐1042, in Refractory Cancer Patients in a Phase I Dose Escalation Study
2004
Topoisomerase I inhibitors: topotecan and irenotecan
1994
Doxil® — The first FDA-approved nano-drug: Lessons learned
2012 Standout
Topoisomerase I inhibitors: Review and update
1997
Induction of cleavage in topoisomerase I c-DNA by topoisomerase I enzymes from calf thymus and wheat germ in the presence and absence of camptothecin
1993 StandoutNobel
Camptothecin and Its Analogs
1996
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
2000 Standout
Liposomes as nanomedical devices
2015 Standout
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
2000 Standout
DNA filter elution: A window on DNA damage in mammalian cells
1996 StandoutNobel
In vitro mutagenesis and functional expression inEscherichia coliof a cDNA encoding the catalytic domain of human DNA ligase I
1991 StandoutNobel
A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma
2008
A New Water‐soluble Camptothecin Derivative, DX‐8951f, Exhibits Potent Antitumor Activity against Human Tumors in vitro and in vivo
1995
Hepatocellular carcinoma pathogenesis: from genes to environment
2006 Standout
Nanoparticle and targeted systems for cancer therapy
2004 Standout
Nonresectional therapies for hepatocellular carcinoma
1997
Topoisomerase I inhibitors: camptothecins and beyond
2006 Standout
Camptothecins
2002
Hepatocellular carcinoma
2022 Standout
Poly (amino acid) micelle nanocarriers in preclinical and clinical studies
2008
Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor
1998
Camptothecins: from bench research to hospital wards.
1994
Chemical Topology: Complex Molecular Knots, Links, and Entanglements
2011 StandoutNobel
Clinical pharmacokinetics of doxorubicin in hepatoma patients after a single intravenous injection of free or nanoparticle-bound anthracycline
1989
Novel SN-38–Incorporating Polymeric Micelles, NK012, Eradicate Vascular Endothelial Growth Factor–Secreting Bulky Tumors
2006
DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in Xenografts
1989 Science
A Phase I and Pharmacokinetic Study of Pegylated Camptothecin as a 1-Hour Infusion Every 3 Weeks in Patients With Advanced Solid Malignancies
2002
Antiviral Action of Camptothecin
1972
Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
2005
Molecular Modeling Studies of the DNA−Topoisomerase I Ternary Cleavable Complex with Camptothecin
1998 StandoutNobel
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
2009 Standout
Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites.
1995 StandoutNobel
Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients
1985 Standout
Sesquiterpenoids Lactones: Benefits to Plants and People
2013 Standout
A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures.
1993
Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein
1989
Biodegradable polymers as biomaterials
2007 Standout
Applications of magnetic nanoparticles in biomedicine
2003 Standout
Topoisomerase I Inhibitors: An Overview of the Camptothecin Analogs
1994
Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas
2005
Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.
1987
Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin.
1989
Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone
2016
Role of Quinones in Toxicology
2000 Standout
Phase I Trial of Poly-l -Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies
2007
Hepatocellular carcinoma
2000
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Irinotecan Combined With Bolus Fluorouracil, Continuous Infusion Fluorouracil, and High-Dose Leucovorin Every Two Weeks (LV5FU2 Regimen): A Clinical Dose-Finding and Pharmacokinetic Study in Patients With Pretreated Metastatic Colorectal Cancer
1999
Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications
2012 Standout
Targeted Disruption of the Mouse Topoisomerase I Gene by Camptothecin Selection
1996 StandoutNobel
Multiple event activation of a generic prodrug trigger by antibody catalysis
1999 StandoutNobel
Systemic chemotherapy for hepatocellular carcinoma
1992
Ribosome Formation is Blocked by Camptothecin, a Reversible Inhibitor of RNA Synthesis
1971
DNA Topoisomerases: Structure, Function, and Mechanism
2001 Standout
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
1992 StandoutScience
Works of Block Jb being referenced
Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).
1970
Vitamin K3 inhibition of malignant murine cell growth and human tumor colony formation.
1985
Doxorubicin cytotoxicity enhanced by local anesthetics in a human melanoma cell line.
1982
Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results.
1984
Preliminary observations on temperature-enhanced drug uptake by leukemic leukocytes in vitro.
1976